MFN News & Analysis
2 articles
Market Mood
RXO (NYSE:RXO) Hedge Fund Increases Position by 532,276 Shares
MFN Partners Management, LP disclosed a purchase of 532,276 shares of RXO (NYSE:RXO) valued at $7.81 million, according to a May 14, 2026, SEC filing. Post-purchase, RXO comprises 8.61% of MFN's reportable 13F assets. RXO's shares were priced at $19.81 as of May 13, 2026, reflecting a one-year increase of 19.19%, while underperforming the S&P 500 by 7.27 percentage points. Year-to-date, RXO shares have advanced by 93%, significantly outperforming the S&P 500's 10% gain.
Read More
Novartis (NVS) CEO Warns of Drug Pricing Policy Impact in 18 Months
Novartis (NVS) CEO Vas Narasimhan indicated that the U.S. drug pricing policy under President Trump, particularly the most favored nation (MFN) policy, could create significant challenges for drugmakers and patients in the next 18 months. This policy currently impacts around 5-10% of Medicaid sales for Novartis. The CEO emphasized the need for European and Japanese governments to modify their reward systems for drug innovation to avoid delayed access to new medicines. Furthermore, Germany's recent cost-cutting proposals could exacerbate the issue, raising concerns about the future of drug availability in these markets.
Read More